📖
Repositioning of moxidectin: a promising approach in cutaneous leishmaniasis therapy
Lynn Al Samra, Mohamad El Nahas, Ilham Mneimneh, Sima Tokajian, Georges Nemer, Aia Sinno, Kelven Rahy, Sergio Thoumi, Zahraa Zibara, Ahmad El Khatib, Dalal Sabbagh, Jacques Guillot, Louna Karam, Lazo Ali, Ruqaya Baghdadi, Charbel Al Khoury

Repositioning of moxidectin: a promising approach in cutaneous leishmaniasis therapy

Science & Mathematics Published 2025 Verification Pending

Overview & Synopsis

Cutaneous leishmaniasis presents a significant challenge to public health due to its diverse clinical manifestations, resistance development, and treatment-related adverse effects. Here, we examined the efficacy of ivermectin, moxidectin (MOX), afoxolaner, and permethrin against all stages of Leishmania tropica and THP-1 cells. We also assessed the potential for resistance acquisition after 15 rounds of artificial selection. To elucidate the mode of action of MOX, we employed RNA sequencing, molecular dynamics simulation, and chloride flux assays. Additionally, we evaluated the therapeutic index of MOX using the Galleria mellonella infection model. MOX demonstrated the highest selectivity index against leishmaniasis (promastigotes: 0.58 μM; amastigotes: 0.96 μM; host cells: 60.29 μM). Moreover, MOX exhibited the lowest resistance acquisition in both promastigotes and intracellular amastigotes after 15 rounds of artificial selection, with resistance ratios of 17.23 and 4.59, respectively. Post-exposure to MOX, differential gene expression profiles showed both stage-specific and stage-unspecific enrichment of gene families involved in crucial biological processes. Moreover, molecular dynamics simulations revealed a potential neutralizing effect of MOX on the chloride channel of L. tropica. Specifically, MOX binds to the selectivity filter, potentially disrupting the osmotic equilibrium and thereby killing the parasite. The in vivo introduction of MOX significantly inhibited the growth of L. tropica in G. mellonella larvae, resulting in decreased rates of mortality and melanization. These findings indicate that MOX is a promising candidate for the treatment of L. tropica infections, warranting further investigation and potential consideration for clinical use.

Indexed from repository: HAL Open Science (hal.science)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Repositioning of moxidectin: a promising approach in cutaneous leishmaniasis therapy
Author / Organization Lynn Al Samra, Mohamad El Nahas, Ilham Mneimneh, Sima Tokajian, Georges Nemer, Aia Sinno, Kelven Rahy, Sergio Thoumi, Zahraa Zibara, Ahmad El Khatib, Dalal Sabbagh, Jacques Guillot, Louna Karam, Lazo Ali, Ruqaya Baghdadi, Charbel Al Khoury
Subject & Discipline Multidisciplinary Academic Open Research
Categories Science & Mathematics
Publication Year 2025
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website HAL Open Science (hal.science)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-202862
Original Source Link Visit Source Page on hal.science »